Rusfertide

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), highlighted phase 2 data investigating hepcidin mimetics for polycythemia vera that appears to have eliminated the need for phlebotomy.

Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit below 45% without phlebotomy, according to a study presented at ASH Annual Meeting and Exposition.